Embecta Corp. reported fiscal Q3 2026 results and plans a conference call today at 8 a.m. ET.
Quiver AI Summary
Embecta Corp., a company with a century-long legacy in insulin delivery, announced its financial results for the third quarter of fiscal 2026. The press release was issued on August 7, 2026, and includes details about a conference call and live audio webcast for analysts and investors scheduled for the same day at 8:00 a.m. ET. The call can be accessed online, with a replay available starting at 11:00 a.m. ET, and archived on the company's investor relations site for a year. Embecta is focused on expanding its operations beyond insulin delivery into a broader medical supplies company, driven by innovative solutions and a dedicated workforce of about 2,000 employees worldwide. More information can be found on their website and social media channels.
Potential Positives
- Embecta Corp. reported its third quarter fiscal 2026 financial results, indicating ongoing business activity and potential growth.
- The company is transitioning from a focus on insulin delivery to becoming a broad-based medical supplies company, suggesting strategic diversification and long-term vision.
Potential Negatives
- The press release does not include specific financial metrics or performance indicators, which may lead to concerns about transparency and the company's current financial health.
- There is no mention of growth or profit projections, which could signal potential stagnation or lack of strategic direction in a competitive market.
- The focus on evolving from an insulin delivery company to a broad-based medical supplies company may imply challenges in adapting to a broader market, raising questions about core competencies.
FAQ
What are Embecta Corp's latest financial results?
Embecta Corp. reported its third quarter fiscal 2026 financial results on August 7, 2026.
How can I access Embecta's earnings press release?
You can view the detailed third quarter fiscal 2026 earnings press release on the company's Investor Relations website.
When is the conference call for investors?
The conference call for analysts and investors will be held on August 7, 2026, at 8:00 a.m. ET.
Where can I find the webcast replay of the conference call?
The webcast replay will be available beginning at 11:00 a.m. ET on August 7, 2026, on the investor relations website.
What is Embecta Corp's mission?
Embecta aims to advance its legacy in insulin delivery and become a broad-based medical supplies company.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EMBC Revenue
$EMBC had revenues of $221.8M in Q2 2026. This is a decrease of -14.36% from the same period in the prior year.
You can track EMBC financials on Quiver Quantitative's EMBC stock page.
You can access data on EMBC stock through the Quiver Quantitative API.
$EMBC Hedge Fund Activity
We have seen 114 institutional investors add shares of $EMBC stock to their portfolio, and 160 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RIVER ROAD ASSET MANAGEMENT, LLC removed 3,449,502 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $11,245,376
- SIO CAPITAL MANAGEMENT, LLC added 1,847,850 shares (+inf%) to their portfolio in Q1 2026, for an estimated $16,334,994
- AMERICAN CENTURY COMPANIES INC removed 1,482,455 shares (-30.1%) from their portfolio in Q1 2026, for an estimated $13,104,902
- YACKTMAN ASSET MANAGEMENT LP added 1,408,962 shares (+62.3%) to their portfolio in Q1 2026, for an estimated $12,455,224
- KRENSAVAGE ASSET MANAGEMENT, LLC added 735,340 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,500,405
- WALLEYE CAPITAL LLC removed 716,917 shares (-90.4%) from their portfolio in Q2 2026, for an estimated $2,337,149
- SG AMERICAS SECURITIES, LLC added 603,106 shares (+138.4%) to their portfolio in Q1 2026, for an estimated $5,331,457
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$EMBC Price Targets
Multiple analysts have issued price targets for $EMBC recently. We have seen 2 analysts offer price targets for $EMBC in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Travis Steed from B of A Securities set a target price of $3.0 on 05/18/2026
- Anthony Petrone from Mizuho set a target price of $5.0 on 05/06/2026
Full Release
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.
Visit the company’s Investor Relations website at http://investors.embecta.com to view the detailed third quarter fiscal 2026 earnings press release and investor presentation.
The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, Aug 7, 2026, which is accessible here , or access the teleconference here . The live webcast can also be accessed via the company’s website at investors.embecta.com .
A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 7, 2026, via the embecta investor relations website and archived on the website for one year.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn , Facebook , and Instagram .
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
